The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in patients ≥75 years old, suffering from stable angina, silent ischemia (1 month DAPT) or acute coronary syndromes (6 months DAPT) related to significant coronary artery disease and requiring percutaneous coronary intervention.
ID: NCT02099617
Sponsor
Sponsors
Primary endpoints
Composite rate of Major Cardiovascular and Cerebrovascular Events (all-cause death, myocardial infarction, stroke, ischemia-driven target lesion revascularization) at one year
CERC Services
- Full Services
Countries
Belgium, Finland, France, Italy, Latvia, Macedonia, Spain, Switzerland and UK managed by CERC
Number of investigational sites
43
